실시간
FierceBiotechADA: Boehringer execs claim survodutide tolerability 'consistent' with class despite phase 3 updateFierceBiotechRoche bets $700M upfront on Nurix’s late-phase BTK degrader to tee up Lilly showdownBioPharma DiveInnovation alone is no longer enough in biopharmaBioPharma DivePrecision under pressure: Logistic solutions for nuclear medicine scalabilityRoche MediaRoche Korea picks 4 Korean biotech firms for K-Swiss BioPass program - koreabiomed.comFierceBiotechCould engaging the immune system improve AML outcomes?FierceBiotechWhy AI is changing clinical developmentFierceBiotechManaging complexity across biopharma modalitieseLifeA macroevolution-inspired approach to reveal novel antibiotic resistance mechanismseLifeA comprehensive mechanosensory connectome reveals a somatotopically organized neural circuit architecture controlling stimulus-aimed grooming of the <i>Drosophila</i> headNINGBO YONGXIN OPTICS CO., LTD.World Microscope Objectives - Market Analysis, Forecast, Size, Trends and Insights - IndexBoxEndpoints News#ADA26: 19% of Phase 3 patients quit Boehringer obesity shot over side effects
Endpoints News 2026년 1월 21일

The status of EU drug price talks depends on who you ask

The status of EU drug price talks depends on who you ask

원문
본문을 이용할 수 없습니다. 원본 출처를 확인하세요.